VTRU200 / VITRUVIAE - LARVOL DELTA

Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager (ASH 2024) - "Additional structure activity relationship testing revealed that the potency of the molecule could be further improved when employing a more proximal anti-CD3 domain (to facilitate synapse formation between T cells and tumor cells) and thus, this optimized structure (VTRU200) was selected as the lead molecule for further preclinical and clinical development...In conclusion, we validated two highly promising non-protein targets for AML immunotherapy and developed innovative T cell engager-based Man9/PS dual targeting strategies characterized by the absence of on-target off-tumor toxicity and antigen negative relapse potential, which are major safety and efficacy limitations of currently available immunotherapies. Our goal is to develop a first-in-class, breakthrough Man9 x PS x CD3 trispecific T cell engager for AML patients with an anticipated timeline to IND of 18 months."

IO biomarker • Pan tumor • Trispecific • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD8 • KIM1

Employing novel pan-cancer targets for immunotherapy in leukemias and solid tumors. (ASCO 2025) - "In vivo studies in human CD3 transgenic mice treated with intravenous doses of VTRU200 (Man9 x PS x CD3) showed significant therapeutic responses, based on in vivo bioluminescence imaging... Our data supports Man9 and PS as promising non-protein targets for pan-cancer immunotherapy. The dual targeting approach with T cell engagers reduces on-target, off-tumor toxicity and antigen-negative relapse, advancing a first-in-class Man9 x PS x CD3 trispecific T cell engager. We have also designed and validated a bispecific (Man9 x PS) chimeric antigen receptor (CAR) and research is ongoing for CAR-T therapy for pancreatic cancer."

IO biomarker • Pan tumor • Acute Myelogenous Leukemia • Brain Cancer • Hematological Malignancies • Leukemia • Oncology • Pancreatic Cancer • Solid Tumor • CD8